|
Michael C. Venuti is currently Chief Executive Officer of BioSeek, Inc. Dr. Venuti was formerly an Operating Partner at TPG Growth Biotech Ventures. Prior to TPG, he was the Acting Chief Executive Officer and Chief Scientific Officer of Discovery Partners International, Inc. prior to its merger with Infinity in September 2006. Dr. Venuti was a member of the Discovery Partners' Board of Directors since May 2003, and joined Discovery Partners as Chief Scientific Officer in April 2005. Previously, he was Senior Vice President of Pharmacogenomics, and was named Senior Vice President of Research and General Manager of Celera South San Francisco when Applera Corporation-Celera Genomics Group acquired Axys Pharmaceuticals in 2001. From 1994 through 2001, Dr. Venuti was Director of Medicinal Chemistry, and then Chief Technical Officer, for Axys Pharmaceuticals and its predecessor company, Arris Pharmaceutical Corporation, where he had overall responsibility for ten major pharma collaborations, and was responsible for the founding of a profitable combinatorial chemistry business later sold to Discovery Partners.
From 1988 - 1993, Dr. Venuti was Director of Bioorganic Chemistry at Genentech, Inc., leading the first group of medicinal chemists established in biotech to exploit the tools of recombinant DNA-based technology as applied to drug discovery. From 1980-1988, at Syntex Research, he led a medicinal chemistry group in the areas of enzyme inhibition and biochemical probes.
Dr. Venuti received an A.B. in Chemistry from Dartmouth College, a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology, and completed postdoctoral training at the Institute of Organic Chemistry at Syntex Research, Palo Alto, California. Dr. Venuti has also held an appointment as Adjunct Professor of Chemistry in the Department of Pharmaceutical Chemistry at the University of California, San Francisco, since 1992.
|
